Drug search by name

Sutent and Liver disease

Result of checking the interaction of drug Sutent and disease Liver disease for safety when used together.

Check result:

Sutent <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of sunitinib has been associated with hepatotoxicity, including hepatic failure and in some cases with fatal outcomes. Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with sunitinib. Safety in patients with ALT or AST >2.5 × ULN or, if due to liver metastases, >5.0 × ULN has not been established. Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting or existing hepatic impairment. Obtain periodic liver function testing and withhold for Grade 3 or 4 drug-related hepatic adverse events. Discontinued if symptoms of pancreatitis or hepatic failure are present. Do not restart sunitinib if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.

Sutent

Generic Name: sunitinib

Brand Name: Sutent

Synonyms: n.a.

What is Sutent?